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1. Introduction  
Traumatic brain injury (TBI) has until recently been considered a rare cause of loss of 
pituitary function, accounting for less than one percent of all new cases of hypopituitarism. 
Newer studies have, however, indicated otherwise, and overlooking the condition in case of 
the life-threatening adrenal insufficiency after brain trauma may be fatal (Schneider et al., 
2007a). Thus, chronic anterior pituitary hormone deficits have been described with a higher 
frequency than previously anticipated and have caused expert panels to propose 
recommendations for routine assessment of pituitary function after TBI with appropriate 
replacement of insufficient axes (Ghigo et al., 2005; Ho, 2007; Tanriverdi et al., 2011).  
Most populations have a high incidence of TBI of more than 100 in 100,000 inhabitants. On 
the one hand it is of clinical importance to identify all patients that would benefit from 
relevant substitution therapy, but on the other hand it is also of major socio-oeconomic 
interest to ensure a cost-effective strategy. To perform pituitary testing of all TBI patients 
would be an impossible task both logistically and financially. It is therefore unfortunate that 
the area despite numerous studies still lacks identification of valid predictors for 
development of hypopituitarism, and it has also not yet been clarified, which part of the TBI 
population that should be tested. Additionally, no larger treatment intervention studies 
have been performed, and it therefore remains quite unclear whether or not patients would 
benefit from treatment of hypopituitarism at an early or later stage to facilitate 
neurorehabilitation and improve survival, morbidity and quality of life.  
In this chapter, the published clinical studies of posttraumatic hypopituitarism are 
scrutinized, and current recommendations are discussed in the lines of currently available 
evidence, with reference to socio-oeconomic aspects. 
2. Pathophysiology of hypopituitarism in TBI 
The pituitary gland regulates various endocrine organs including the adrenal cortex, the 
thyroid gland, and the gonads through integration of central and peripheral feedback 
signals. Hypopituitarism refers to an insufficient secretion of pituitary hormones.  
The pathophysiological mechanism of posttraumatic hypopituitarism remains incompletely 
understood, but may include primary mechanical injury to the hypothalamic-pituitary 
region, as well as secondary injury from hypotension, hypoxia, anaemia and brain swelling 
causing restriction of flow in the hypophyseal portal vessels. Support of this 
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pathophysiologic concept comes from autopsy studies of patients with fatal head injury in 
whom up to one-third had anterior pituitary gland necrosis (Ceballos, 1966; Crompton, 
1971; Kornblum & Fisher, 1969). However, whether or not data from fatal cases can be 
generalised to explain long-term hypopituitarism in TBI survivors is not clear. Two MR 
studies showed results supportive of such hypothesis. Firstly, an observational case-control 
study included 41 patients with non-lethal head trauma and demonstrated acute changes 
such as pituitary enlargement, pituitary haemorrhages, infarctions, signal abnormalities 
and/or partial stalk transsection in about 30% of adult TBI patients (Maiya et al., 2007). 
Secondly, other observational data suggested that patients with long-term post-TBI 
hypopituitarism demonstrated more frequently loss of pituitary volume or virtual empty 
sella, abnormal pituitary gland signal heterogeneity, perfusion deficits and/or lack of 
posterior pituitary signal as compared to TBI patients with normal pituitary hormonal 
function (Schneider et al., 2007b). Accordingly, a higher occurrence of midline lesions or 
damage to deep brain structures were reported in hypopituitary patients with diffuse axonal 
injury as compared to those with normal pituitary function (Jeong et al., 2010).  
One group suggested an aetiologic role of anti-pituitary and anti-hypothalamic antibodies 
(Tanriverdi et al., 2010), as well as a genetic predisposition for development of TBI-induced 
hypopituitarism (Tanriverdi et al., 2008a). This has on the other hand not been confirmed in 
other populations. 
In the acute phase post-TBI, the transient effect of stress from critical illness and medication 
are important mechanisms to consider. The following medications are very likely to be 
involved in this patient group in the acute phase, and can by themselves cause life-
threatening adrenal insufficiency: Adrenal cortisol synthesis can be impaired by the 
anaesthetic agent etomidate and the antifungal agent ketokonazol, exogenous corticosteroid 
therapy may suppress the hypothalamo-pituitary-adrenal (HPA) axis and induce adrenal 
atrophy that may persist months after cessation, and hepatic metabolism of cortisol may be 
enhanced by drugs such as phenytoin. 
3. Diagnosing insufficient pituitary function 
The diagnosis of hypopituitarism relies on basal and stimulated anterior pituitary and 
peripheral target hormone concentrations, and diagnostic test-panels and criteria suggesting 
hypopituitarism have been defined (, 1998; Lamberts et al., 1998). Both diagnostic criteria 
and cut-off points are arbitrary, and grey-zones for each pituitary hormone exist. Thus, test 
results must be interpreted in the light of pre-test probability and clinical features (Feinstein, 
1990). Unfortunately, the clinical symptoms in hypopituitarism are most often vague and 
unspecific, and the diagnostic decision therefore often relies on the pre-test probability of 
disease. The diagnostic process is therefore highly challenged by vastly different assays for 
hormone measurements, all having their own reference range, as well as significantly 
different cut-off levels between normal persons and patients with pituitary deficiency. 
Establishment of local diagnostic cut-off points are required, but most often lacking. In most 
centres hypopituitarism is a rare condition, and ensuring own normative data for all the 
pituitary tests is cumbersome and expensive, why many physicians rely on ‘standard’ cut-
off limits from the literature. Ideally, assessment of TBI patients should be restricted to few 
highly specialised collaborative centres using stringent diagnostic criteria for 
hypopituitarism including obligatory confirmation tests in case of an insufficient test 
outcome. The latter is highly important partly due to intraindividual test variation in normal 
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people (Bhasin et al., 2010; Vestergaard et al., 1997), partly due to possible transitory 
changes due to non-pituitary related stress (Fig 1). For logistic reasons such 
recommendation is often not possible. In the following, assessment of each of the clinically 
relevant pituitary axes will be scrutinized. 
3.1 GH deficiency 
Measurement of baseline GH concentrations in serum is rarely informative as the 
secretion of growth hormone (GH) is pulsatile, and stimulation tests estimating the 
secretory capacity are mandatory. The pulsatile release of GH is physiologically 
controlled by stimulation by hypothalamic GH releasing hormone (GHRH) and inhibition 
by the hypothalamic suppressor, somatostatin. GHRH stimulates both GH synthesis and 
secretion, whereas somatostatin inhibits only GH secretion (Giustina & Veldhuis, 1998). 
Multiple neurotransmitter pathways and a variety of peripheral feedback signals 
modulate GH secretion reflected by the large number of accessible stimulation tests, 
relying on many different mechanisms. The GH secretory response to insulin induced 
hypoglycaemia during an insulin tolerance test (ITT) seems to be mediated via stimulated 
GHRH secretion and a concomitant withdrawal of somatostatin inhibition (Giustina & 
Veldhuis, 1998). ITT is considered the diagnostic gold standard, as it is the most 
extensively used and validated test, with very high sensitivity and specificity at standard 
cut-off limits. It has the advantage of allowing evaluation of the integrated hypothalamic-
pituitary function concerning both GH- and adrenocorticotropin (ACTH)- secretions. The 
disadvantage is related to its contraindications including epilepsy and ischaemic heart 
disease, and the fact that it is both unpleasant for the patients and labour-intensive. 
Alternative tests such as the GHRH+arginine and the GHRH-GH releasing peptide 
(GHRP) -6 test have therefore become increasingly popular for assessment of the 
somatotroph function. Arginine acts via inhibition of hypothalamic somatostatin release, 
and GHRP-6 probably antagonizes somatostatin activity, thereby increasing the activity of 
GHRH-neurons (Giustina & Veldhuis, 1998). Because GHRH stimulates the pituitary 
directly, and thus circumvents the hypothalamus, tests involving GHRH may give false 
normal results in the early stage of GHD of hypothalamic origin (Darzy et al., 2003). 
Taking this into account, the GHRHarg test seems to have similar sensitivity and 
specificity as compared with the ITT in lean subjects (Biller et al., 2002). However, the 
GHRHarg is known to depend on the body composition and BMI specific cut-offs are 
needed (Corneli et al., 2005; Makimura et al., 2008). Obesity (Bonert et al., 2004; 
Rasmussen et al., 1995) and relative central adiposity (Miller et al., 2005) are generally 
major confounders by being negative determinants for the stimulated GH concentrations. 
This makes the distinction between organic GHD and obesity difficult, and poses a major 
problem in diagnosing isolated GHD, in particular. On the other hand, independent of 
BMI the likelihood of coexistent severe GHD is more than 90% in patients with two or 
more additional pituitary deficiencies (Toogood et al., 1994). 
3.2 ACTH deficiency 
As a consequence of diurnal rhythmicity dynamic testing of the HPA axis is most often 
required.  A basal morning cortisol can be used under certain circumstances, since a 
concentration less or equal to 100 nmol/L is highly indicative of HPA deficiency (Courtney 
et al., 2000; Watts & Tindall, 1988), whereas a concentration higher than 400 nmol/L is 
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indicative of  HPA sufficiency (Gleeson et al., 2003; Watts & Tindall, 1988). Most commonly 
basal morning cortisol concentrations are in-between, highly overlapping those of healthy 
subjects, and dynamic testing is therefore required eventually. At present, the ITT is 
considered the diagnostic gold standard (Ho, 2007). The test-retest reproducibility is higher 
than for GH (Vestergaard et al., 1997), but false abnormal results can be seen, in particular, if 
only borderline attainment of hypoglycaemia is achieved. The 250 g Synacthen test is often 
used in clinical practice as it is simple, and without contraindications and unpleasant side 
effects. It does have limitations, which include a risk of false normal results e.g. in the early 
phase after hypothalamic or pituitary damage (Klose et al., 2005), as well as in patients with 
partially degenerated adrenal glands. Irrespective of test preference, there are common 
problems in interpretation of results and in choice of cut-off level distinguishing normality 
from HPA deficiency related to the cortisol-assay used (Clark et al., 1998; Klose et al., 2007c), 
presence of dysproteinaemia and medical treatment with oestrogens (Bonte et al., 1999; 
Kirschbaum et al., 1999), either as replacement therapy in gonadal insufficiency or as oral 
contraceptive. 
3.3 TSH deficiency 
Central hypothyroidism is suspected in patients with low total- (T) or free- (f) T4 and an 
inappropriately low TSH. Peripheral thyroid hormone levels have a narrow individual 
reference range compared with that observed between-individuals (Andersen et al., 2002; 
Feldt-Rasmussen et al., 1980). The diagnosis therefore depends on the position of the 
individual's normal set point, which is reflected by TSH in primary hypothyroidism. 
Whereas measurement of TSH is of major diagnostic importance in primary 
hypothyroidism, it is of little use in secondary hypothyroidism of hypothalamic or pituitary 
origin. Most of these patients have a serum TSH within the normal range or even elevated. 
This apparent contradiction may, to some extent at least, be explained by reduced 
bioactivity of the circulating TSH (Beck-Peccoz et al., 1985), probably through abnormal 
glycolysation of the molecule (Oliveira et al., 2001), though the mechanism is not fully 
understood. The diagnosis of secondary hypothyroidism is thus challenging, as the usual 
diagnostic criteria based on a normal reference range are not valid. Isolated secondary 
hypothyroidism is extremely rare and in these patients, samples should be re-analysed by 
an alternative assay, and low thyroxine binding globulin (TBG) concentrations and non-
thyroidal illness have to be excluded before the final diagnosis (Lamberts et al., 1998). 
Stimulation with thyrotropin releasing hormone (TRH) has given discrepant results 
(Franklyn, 1997; Hartoft-Nielsen et al., 2004; Lania et al., 2008). The possible confounding by 
certain antiepileptic drugs is well-described (Cansu et al., 2006; Isojarvi et al., 2001), 
inducing a biochemical picture mimicking that of secondary hypothyroidism with 
decreased peripheral thyroid hormone concentrations and a normal TSH. 
3.4 LH and FSH deficiency  
In postmenopausal women hypogonadotropic hypogonadism is characterised by 
inappropriately low gonadotropins, and in premenopausal women by amenorrhoea or 
oligomenorrhoea in addition to low oestradiol and low or normal gonadotropins. Low 
testosterone and a correspondingly low LH suggest hypogonadotropic hypogonadism in 
men. Due to the diurnal rhythmicity morning samples are required, and in case of a low or 
low normal testosterone concentration sampling must be repeated, because 30% of such 
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men may have a normal testosterone level on repeat measurement (Bhasin et al., 2010; 
Brambilla et al., 2007). Patients with altered sex hormone binding globulin (SHBG) 
concentrations are a major diagnostic challenge. According to the The Endocrine Society 
Clinical Practice Guideline, men in whom total testosterone is near the lower limit of normal 
or in whom SHBG abnormalities are suspected, evaluation should include measurement of 
free or bioavailable testosterone levels using validated assays(Bhasin et al., 2010). 
Conditions associated with high SHBG levels are aging, hepatic cirrhosis and hepatitis, 
hyperthyroidism, use of anticonvulsants, whereas decreased SHBG levels are seen in 
obesity, hypothyroidism, nephritic syndrome, diabetes mellitus, and use of glucocorticoids 
and androgenic steroids.  
3.5 ADH deficiency 
Central ADH deficiency is suspected in patients with polydipsia and polyuria (urine 
volume > 3 litres/24 hours). Urine analysis demonstrates dilute urine with low specific 
gravity and low osmolality. A fluid deprivation test may be necessary in case of 
intermediary results, or in order to determine the type of diabetes insipidus (central versus 
nephrogenic or dipsogenic). 
4. Prevalence of acute hypopituitarism in TBI 
A number of studies have assessed the acute neuroendocrine changes following TBI, in 
order to investigate their correlation to trauma severity, metabolic derangement and 
variables that may predict outcome (Cernak et al., 1999; Cohan et al., 2005; Della et al., 1998; 
Feibel et al., 1983; Hackl et al., 1991). The clinical implications of these findings remain 
unclear. 
Four longitudinal studies have been designed to evaluate the relationship between acute 
and long-term pituitary hormone status after TBI. Agha et al. (Agha et al., 2005a) found 
secondary gonadotropin-, GH-, ACTH - and TSH deficiency in 80%, 18%, 16% and 2%, 
respectively of 56 patients with moderate or severe TBI. At one-year follow-up hormonal 
abnormalities had recovered in most patients, whereas others had developed de novo 
deficiencies, and although persistent GH and ACTH deficiency was associated with more 
severe hyposecretion of GH and cortisol during the acute phase, the authors were unable 
to identify biochemical predictors of long-term hypopituitarism. Tanriverdi et al. 
(Tanriverdi et al., 2006) reported pituitary hormone deficiency in 50% of 52 evaluated 
patients, primarily affecting the gonadothroph axis. However, individual data showed no 
obvious relationship between early and late pituitary dysfunctions. We (Klose et al., 
2007b) described acute hormone alterations in 76% of 46 patients, with patients suffering 
the most severe TBI exhibiting the highest prevalence of alterations mimicking 
hypogonadotropic hypogonadism, central hypothyroidism, hyperprolactinaemia, and 
increased HPA-activity, all in agreement with the alterations seen in non-pituitary critical 
illness (Fig. 1). 
We were unable to identify biochemical predictors of persistent hypopituitarism, and did 
not find any de novo deficiencies from 3 to 12 months post-TBI, whereas late recovery was 
observed in 1 of the 7 patients that were hypopituitary at 3 months. Kleindienst et al. 
(Kleindienst et al., 2009) described hormone alterations in 83% of 71 patients, recovering in 
most within 2 years follow-up. They reported that initial low GH levels predicted persistent 
deficiency 2 years post-TBI. The existing data, however, relies on rather small cohorts only 
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allowing for case description and therefore clear conclusions and recommendations on this 
issue are still not possible. 
 
 
Fig. 1. Simplified concept of the pituitary-dependent changes during the course of critical 
illness. In the acute phase of illness (first hours to a few days after onset), the secretory 
activity of the anterior pituitary is essentially maintained or amplified, whereas anabolic 
target organ hormones are inactivated. Cortisol levels are elevated in concert with ACTH. In 
the chronic phase of protracted critical illness (intensive care dependent for weeks), the 
secretory activity of the anterior pituitary appears uniformly suppressed in relation to 
reduced circulating levels of target organ hormones. Impaired anterior pituitary hormone 
secretion allows the respective target organ hormones to decrease proportionately over time, 
with cortisol being a notable exception, the circulating levels of which remain elevated 
through a peripheral drive, a mechanism that ultimately may also fail. The onset of recovery 
is characterized by restored sensitivity of the anterior pituitary to reduced feedback control. 
(Adapted from Van den Berghe, G (1998) Clinical review 95: Acute and prolonged critical 
illness as different neuroendocrine paradigms. Journal of Clinical Endocrinology and 
Metabolism, 83 (6), pp. 1827-1834). 
Case reports have provided clinical data to justify an increased attention towards potential 
occurrence of secondary hypoadrenalism from the acute phase in TBI patients. In order to 
illustrate the possible pitfall in diagnosing the causes of hyponatraemia in TBI patients, 
Agha et al. (Agha et al., 2007) reported data from 3 patients with severe TBI, who were 
initially misdiagnosed as syndrome of inappropriate ADH secretion (SIADH). In two of the 
cases hypoadrenalism was subsequently suspected due to the combination of 
hyponatraemia, hypoglycaemia and hypotension, and in the third case because plasma 
sodium did not correct with fluid restriction. All three patients had extremely low baseline 
cortisol concentrations of 33 – 110 nmol/L, and undetectable ACTH levels. The condition 
ameliorated in all upon glucocorticoid replacement. It should be emphasized that patients 
may present with more subtle signs and symptoms, and still be life-threatened by 
undiagnosed hypoadrenalism. 
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5. Prevalence of chronic hypopituitarism in TBI 
Anterior pituitary hormone deficiency following TBI has traditionally been considered very 
rare, and mainly reported as single cases or series of cases. Over the last 10 years, the field 
has received increased attention and chronic anterior pituitary hormone deficiency has been 
reported with a prevalence ranging from 1% and up to 83% (Table 1). The results from most 
studies have suggested that persistent posttraumatic hypopituitarism might be a more 
common complication in TBI than previously believed, although some studies have failed to 
show such high occurrence rates (Kokshoorn et al., 2011; van der Eerden et al., 2010). 
The diversity of the reported prevalences of chronic anterior pituitary hormone deficiency is 
likely to be explained by differences in study populations, study designs, and diagnostic 
procedures. Trauma severity varied considerably among the studies (Table 1). In general, a 
lower prevalence of posttraumatic hypopituitarism tended to be recorded in studies 
recruiting less severely injured patients (Kokshoorn et al., 2011; van der Eerden et al., 2010), 
and indicators of increased trauma severity was also suggested to be associated with 
development of hypopituitarism by some (Bavisetty et al., 2008; Bondanelli et al., 2004; Kelly 
et al., 2000; Klose et al., 2007a; Schneider et al., 2008), while not by others (Agha et al., 2004; 
Aimaretti et al., 2005; Leal-Cerro et al., 2005). In 22 TBI patients Kelly et al.(Kelly et al., 2000) 
identified injury severity in terms of an initial Glasgow Coma Scale score (GCS) of less than 
10, diffuse brain swelling and hypoxia/hypotension as risk factors of posttraumatic 
hypopituitarism. Bavisetty et al. (Bavisetty et al., 2008) found that the degree of injury as 
defined by acute cerebral CT was the strongest predictor for long-term pituitary deficiencies, 
and in the cohort examined by us (Klose et al., 2007a), a normal CT excluded development 
of long-term deficiencies. On the other hand, the role of acute CT was recently contradicted 
by Kleindienst el al (Kleindienst et al., 2009) who found no relationship between acute or 
late CT findings and development of hypopituitarism. Other surrogate measures of trauma 
severity have been suggested to predict post-TBI hypopituitarism, including increased 
intracranial pressure (Klose et al., 2007a), diffuse axonal injury and basal skull fractures 
(Schneider et al., 2008). 
Recently, Kokshoorn et al. (Kokshoorn et al., 2010) questioned the considerable variation of 
the reported prevalence, and assessed the impact of methodological differences among the 
present studies. They confirmed that part of the variation indeed seemed to be caused by 
differences in study design, diagnostic procedures, and other confounding factors such as 
BMI, prohibiting simple generalization from the original studies. In general, a lower 
prevalence of posttraumatic hypopituitarism tended to be recorded in studies using the ITT 
for the evaluation of the GH reserve (Kelly et al., 2000; Klose et al., 2007a; Kokshoorn et al., 
2011), and in the studies using confirmatory tests (Agha et al., 2004; Klose et al., 2007a; Leal-
Cerro et al., 2005; van der Eerden et al., 2010).   
Table 2 a-d illustrates the relationship between diagnostic stringency and reported 
prevalence of GH, ACTH, LH/FSH and TSH deficiencies. Diagnostic stringency was rated 
according to information in the publications on pituitary tests, comparison with own and 
sufficient normative data and performance of confirmatory testing, There was an apparent 
association between diagnostic stringency and reported prevalence of GH deficiency  (Table 
2a). The diagnostic cut-offs have varied considerably between studies, and as suspected, the 
reported prevalence of GH deficiency increased with increasing test related cut-off limits. 
Furthermore, some studies only reported severe GH deficiency, whereas others reported 
both severe and partial cases.  
www.intechopen.com
 
Brain Injury – Functional Aspects, Rehabilitation and Prevention 56
 
   Anterior Pituitary Hormone deficiency (%) 
Authors 
n GCS<13 Total 
Multiple 
deficiencies 
GH 
deficiency* 
ACTH 
deficiency 
LH/FSH 
deficiency 
TSH    
deficiency 
Kelly et al., 2000 22 NS 36 23 18^ 5 23 5 
Lieberman et al., 2001 70 NS 69 18 15 46 1 22 
Agha et al., 2004 102 100% 29 6 8 (3) 13 12 1 
Bondanelli et al., 2004 50 86% 54 12 8 (20) 0 14 10 
Popovic et al., 2004 67 100% 34 10 15 (15) 7 9 4 
Aimaretti et al., 2005 70 45% 23 10 20 (16) 7 11 6 
Leal-Cerro et al., 2005 170 b 100% 25 9 6 6 17 6 
Schneider et al., 2006 70 78% 36 4 10 9 20 3 
Tanriverdi et al., 2006 52 40% 51 10 33 19 8 6 
Herrmann et al., 2006 76 100% 24 7 8 2 17 2 
Klose et al., 2007 104 58% 15 6 11 (5) 5 2 2 
Bavisetty et al., 2008 70 NS 21 4 16 0 10 0 
Wachter et al., 2009 53 61% 25 2 2 4 15 6 
Kleindienst et al., 
2009 
23 78% 83 30 39 48 0 0 
v der Eerden et al., 
2010 
107 28% < 1 0 0 < 1 0 0 
Krahulik et al., 2010 87 NS 21 - 14 0 6 0 
Park et al., 2010 45 100% 31 13 20 13 18 7 
Kokshoorn et al., 2011 112 43% 5 1 3 4 1 0 
GCS: Glasgow Coma Scale score; NS: nor specified; *Severe (partial) when reported as such; 
^GHD+GHI; b only 99 patients tested 
Table 1. Present publications on the prevalence of chronic posttraumatic anterior pituitary 
dysfunction. 
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A Diagnostic tests and cut-offs used for the diagnosis of GH deficiency 
Authors Test Cut-offs 
Confirmatory 
test 
Prevalence of 
GH deficiency 
Diagnostic 
stringency 
van der Eerden 
et al., 2010 
GHRH-arg; if 
GHRH-arg response 
low then ITT or 
GHRH-arg 
GHRHarg: peak GH < 3.5ug/l 
ITT: peak GH < 3,4 ug/l 
Yes 0 
 
Kokshoorn et 
al., 2011 
ITT; if 
contraindicated then 
GHRH-arg 
ITT: peak GH < 3 ug/l 
GHRHarg:: 
BMI<25; peakGH < 11 ug/l 
BMI25-30: peakGH <8 ug/l 
BMI>30: peak GH < 4 ug/l 
No 3 
Herrmann et 
al., 2006 
GHRH-arg; if 
GHRH-arg & IGF-1 
low, then additional 
ITT 
GHRH-arg: peak GH < 9 ug/l 
ITT: peak GH < 3 ug/l 
Yes 8 
Klose et al., 
2007 
ITT; if 
contraindicated then 
GHRH-arg 
ITT: peak GH < 3 ug/l 
GHRHarg: peak GH < 9 ug/l 
Yes 11 
Leal-Cerro et 
al., 2005 
If IGF-1 low or 
pituitary deficiency 
other than GHD, 
then GHRH-GHRP-6 
& ITT &. GST 
GHRH-GHRP-6: 
peak GH ≤ 10 ug/l; 
If peak GH 10-20 ug/l then 
confirmed by 
ITT: peak GH < 3 ug/l 
GST: peak GH < 3 ug/l 
Yes 6 
Agha et al., 
2004 
GST; if sub-normal 
then ITT: if ITT 
contra-indicated then 
GHRH-arg 
GST: peak GH <5 ug/l 
ITT: peak GH < 5 ug/l GHRH-
arg: peak GH < 9 ug/l 
Yes 8 
Kleindienst et 
al., 2009 
GHRH-arg peak GH <9 ug/l No 39 
Schneider et al., 
2006 
GHRH-arg peak GH ≤9 ug/l No 10 
Aimaretti et al., 
2005 
GHRH-arg peak GH <9 ug/l No 20 
Bondanelli et 
al., 2004 
GHRH-arg peak GH <9 ug/l No 8 
Lieberman et 
al., 2001 
Glucagon test in a 
NS subset of patients 
peak GH <3 ug/l No 15 
Popovic et al., 
2004 
GHRH-GHRP6 peak GH <10 ug/l No 15 
Tanriverdi et 
al., 2006 
GHRH-GHRP6 peak GH <10 ug/l No 33 
Kelly et al., 
2000 
ITT NS; <5th percentile from 18 HC No 18 
Bavisetty et al., 
2008 
GHRH-arg peak GH < 12 ug/l No 16 
Park et al., 2010 ITT peak GH < 10 ug/l No 20 
Krahulik et al., 
2010 
Arginine or 
GHRH 
Arginine: < 10th percentile of 
HC 
Glucagon: NS 
No 14 - 
Wachter et al., 
2009 
GHRH* NS No 2 - 
Table 2. a. 
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B Diagnostic tests and cut-offs used for the diagnosis of ACTH deficiency 
Authors 
Test Cut-offs 
Confirmatory 
test 
Prevalence of 
ACTH deficiency 
Diagnostic 
stringency 
Kelly et al., 
2000 
ITT 
peak cort below 283 
nmol/l^; pt diagnosed on 
clinical picture 
No 5 
 
Bavisetty et al., 
2008 
LDST peak cort < 331 nmol/l^^ No 0 
Klose et al., 
2007 
ITT; if 
contraindicated then 
SST 
peak cort < 500 nmol/l Yes 5 
Kokshoorn et 
al., 2011 
ITT; if 
contraindicated then 
LDST or SST 
peak cort < 500 nmol/l No 4 
Herrmann et 
al., 2006 
Baseline or ITT, 
selection criteria for 
ITT NS 
baseline cort < 180 nmol/l 
peak cort < 500 nmol/l 
No 2 
Agha et al., 
2004 
GST; if subnormal 
then ITT; if ITT 
contraindicated then 
SST 
GST: peak cort < 450 
nmol/l 
ITT: peak cort < 500 
nmol/l 
SST: peak cort < 500 
nmol/l 
Yes 13 
Leal-Cerro et 
al., 2005 
Basal cortisol; if low 
then ITT 
Basal cort: < 200 nmol/l 
ITT: peak  cort < 550 
nmol/l     +   peak ACTH < 
6.6 pmol/l 
Yes 6 
van der Eerden 
et al., 2010 
Basal cortisol; if low 
then ITT 
basal cort < 200 nmol/l 
peak cort < 550 nmol/l 
Yes < 1 
Schneider et al., 
2006 
SST peak cort < 500 nmol/l No 9 
Tanriverdi et 
al., 2006 
Basal cortisol; if low 
then LDST 
basal cort: < 193 nmol/l 
LDST: peak cort < 550 
nmol/l 
No 19 
Park et al., 2010 ITT peak cort: < 550 nmol/l No 13 
Kleindienst et 
al., 2009 
SST peak cort: < 550 nmol/l No 48 
Aimaretti et al., 
2005 
Basal morning 
cortisol and UFC 
9.00 h cort: < 220 nmol/l 
(evt. low 24-h UFC) 
No 7 
Bondanelli et 
al., 2004 
Basal morning 
cortisol 
basal cort: < 220 nmol/l No 0 
Lieberman et 
al., 2001 
Basal cortisol basal cort: < 193 nmol/l No 46* 
Krahulik et al., 
2010 
If basal cortisol < 500 
nmol/l, then ACTH 
test 
peak cort: < 5th percentile 
of HC, NS 
No 0  
Wachter et al., 
2009 
CRH NS No 4 - 
Popovic et al., 
2004 
Basal morning 
cortisol 
NS No 7 - 
Table 2. b. 
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C 
Diagnostic tests and cut-offs used for the diagnosis of LH/FSH deficiency 
Authors Test Cut-offs 
Confirmatory 
test 
Prevalence 
of LH/FSH 
deficiency 
Diagnostic 
stringency 
Kleindienst 
et al., 2009 
Baseline 
[M: T < 3,1 nmol/dl 
preF: E < 60 pg/dl 
postF: E < 10 pg/dl] + inapp low LH&FSH 
No 0 
 
Tanriverdi 
et al., 2006 
Baseline 
M: T < 4,6 nmol/l + low/norm LH/FSH 
preF: E < 40 pmol/l+inapp low LH/FSH 
post F: LH&FSH in premenopausal range 
No 8 
Klose et al., 
2007 
Baseline 
M: T < 10 nmol/l & inapp low LH 
preF: a-/oligomenorrhea + low E & inapp low 
LH&FSH 
postF: LH&FSH in premenopausal range 
Yes 2 
van der 
Eerden et 
al., 2010 
Baseline 
M: T < 11 nmol/l & low fT & low/norm 
LH&FSH 
preF: amenorrhea, low E & low/norm 
LH&FSH 
postF: low gonadotropins 
Yes 0 
Leal-Cerro 
et al., 2005 
Baseline; 
if low 
then 
GnRH 
test 
M: fT below age dependant ref & low /norm 
LH&FSH 
F: menstrual distb.+ low E+low/norm 
LH&FSH 
GnRH: peak LH<10 fold increment above base-
line & peak LH > 10 U/l 
Yes 17 
Herrmann 
et al., 2006 
Baseline 
M: T < 9,5 nmol/l + low/normal LH/FSH 
preF: amenorrhea + low E 
postF: LH&FSH in premenopausal range 
No 17 
Agha et al., 
2004 
Baseline 
M: T < 10.3 nmol/l + low/normal LH&FSH 
preF: amenorrhea + low E 
postF: LH/FSH in premenopausal range 
No 12 
Aimaretti et 
al., 2005 
Baseline 
M: T < 10 nmol/l + low/normal LH/FSH 
preF: menstrual disturb. + E < 20pg/ml 
No 11 
Bondanelli 
et al., 2004 
Baseline 
M: T < 10 nmol/l + low/normal LH/FSH 
F: NS 
No 14 
Bavisetty et 
al., 2008 
Baseline 
 
M: T < 10 nmol/l ^ 
F: E < 27.6 pg/ml + menstrual disturb. 
No 10 
Schneider 
et al., 2006 
Baseline 
M: T < 12 nmol/l + low/norm LH&FSH 
preF: amenorea after TBI 
postF: inapp low LH&FSH 
No 20 
Kelly et al., 
2000 
M. GnRH 
F: 
Baseline 
NS No 23  
Lieberman 
et al., 2001 
Baseline; 
if low 
then 
GnRH 
M: low T (NOS) 
F: menstrual history 
No 1  
Popovic et 
al., 2004 
Baseline 
M: NS 
F: menstrual history 
No 9  
Wachter et 
al., 2009 
Baseline 
/ TRH 
NS No 15  
Krahulik et 
al., 2010 
Baseline 
M: T<5th perc form HC 
F: menstrual history; low E 
No 6  
Park et al., 
2010 
Baseline 
(M: low T; Pre F: low E  with inapp low 
gonadotropins. Post F: LH/FSH in 
premenopausal range 
No 18  
Table 2. c.  
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D 
Diagnostic tests and cut-offs used for the diagnosis of TSH deficiency 
Authors 
Test Cut-offs 
Confirmatory 
test 
Prevalence of 
TSH 
deficiency 
Diagnostic 
stringency 
van der Eerden 
et al., 2010 
Baseline 
fT4 < 8 pmol/l & 
norm/low TSH 
Yes 0 
 
Leal-Cerro et al., 
2005l. 
Baseline; if 
low then 
TRH 
fT4 < 7,7 pmol/l & norm/low 
TSH 
TRH: TSH peak < 7 mU/ml 
Yes 6 
Agha et al., 2004l. Baseline 
fT4  < 8 pmol/l & 
norm/low TSH 
No 1 
Bondanelli et al., 
2004. 
Baseline 
fT4 < 10,3 pmol/l & 
norm/low TSH 
No 10 
Aimaretti et al., 
2005. 
Baseline 
fT4 < 10,3 pmol/l & 
norm/low TSH 
No 6 
Tanriverdi et al., 
2006. 
Baseline 
fT4 < 10,3 pmol/l & 
norm/low TSH 
No 6 
Kleindienst et al., 
2009. 
Baseline 
fT4 < 10 pmol/l or TT3 < 0,8 
ng/dl & TSH < 0,45 U/L 
No 0 
Herrmann et al., 
2006. 
Baseline 
fT4 < 10 pmol/l & 
norm/low TSH 
No 2 
Bavisetty et al., 
2008. 
Baseline 
Low TT4  (NS) and 
fT4 < 10 pmol/l^ 
No 0 
Klose et al., 2007. Baseline 
fT4 < 12 pmol/l & 
norm/low TSH 
Yes 2 
Schneider et al., 
2006 
Baseline 
fT4 < 12 pmol/l & 
norm/low TSH 
No 3 
Lieberman et al., 
2001 
Baseline; 
TRH in 
some (NS) 
Low fT4 and normal/low 
TSH; or normal fT4 and low 
TSH 
TRH: TSH < 5mU/l 
No 22 
Wachter et al., 
2009 
Baseline 
TRH 
NS No 6  
Popovic et al., 
2004 
Baseline NS No 4  
Kelly et al., 2000. TRH NS^^ No 5  
Krahulik et al., 
2010. 
Baseline FT4 and TSH (NOS) No 0  
Park et al., 2010l. Baseline 
Low FT4 & 
norm/low TSH; NOS 
No 7  
Kokshoorn et al., 
2011. 
Baseline NS No 0  
BMI: body mass index; cort: cortisol level; disturb: disturbances; E: estradiol; F: females; fT4: free thyroxine; 
ftest: free testosterone; GHD: GH deficiency; GHRHarg: GHRH-arginine test; GHRH-GHRP-6: GHRH-
GHRP-6 test; GnRH: GnRH-test; GST: glucagon stimulation test; HC: healthy control; inapp: 
inappropriately; ITT: insulin tolerance test; LDST: low-dose synacthen test; M: males; norm: normal i.e. 
within the normal range; NOS: not otherwise specified; NS: not specified; preF: premenopausal women; 
postF: postmenopausal women; pt: patient; SST: short synacthen test; test: total testosterone level; TBG: 
thyroid binding globulin; TRH: TRH-test; tT4: total thyroxine; UFC: urine free cortisol; ^5th percentile from 
18 HC; ^^5th percentile from 39 HC; * 7,1 % of the total cohort had a peak cortisol < 500 nmol/l in 
response to the SST. 
Table 2. a-d. Overview of diagnostic procedures and reported prevalence in previous 
studies on chronic posttraumatic hypopituitarism. Studies are ranged according to 
diagnostic stringency based on stimulation tests, cut-off criteria, as well as performance of 
confirmatory tests or not. 
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GH deficiency, being the most frequently observed deficiency in the studies, was often 
found to be positively associated with BMI, which was not surprising as obesity (Bonert et 
al., 2004; Rasmussen et al., 1995) and relative central adiposity (Miller et al., 2005) are major 
confounders, and negative determinants for the stimulated GH concentrations in persons 
without hypothalamo–pituitary disturbances. This makes the distinction between organic 
GH deficiency and obesity difficult or even impossible, and poses a major diagnostic 
problem in isolated GH deficiency, in particular. The earliest TBI studies using the 
GHRH+arg test used a fixed cut-off independent on BMI of the subjects, and only later 
studies adjusted for the known confounding from BMI, by application of BMI related cut-
offs that were then available.  Many of the studies should in fact reanalyse their data with 
this information in hand in order to clarify the ‘true’ number of individuals with GHD, or at 
least less emphasis should be paid on these study results in meta-analyses, reviews and 
recommendations. 
The association between diagnostic stringency and reported prevalence is not as clear when 
it comes to secondary hypoadrenalism. However, the two studies reporting the lowest 
prevalence also applied the most stringent criteria. Kelly et al. defined their cut-off limit for 
the ITT as the 5th percentile of peak GH derived from 18 healthy control subjects. It was not 
further specified, but was somewhat below 283 nmol/l, which is striking. Establishment of 
local diagnostic cut-off points are generally recommended, due to assays dependency. 
However, cut-offs limits, based on 5th percentiles from normative data from such small 
populations, may be heavily influenced by outliers, which may explain the low cut-off limit 
used in this study. This hypothesis seems reinforced by the fact that although passing the 
biochemical definition having peak cortisol of 286 nmol/l, one patient was diagnosed with 
secondary hypoadrenalism on clinical manifestations (Kelly et al., 2000). In the other end of 
the spectrum, Libermann et al. reported a total prevalence of anterior pituitary hormone 
deficiency of 69%, including 46% with secondary hypoadrenalism. The occurrence of 
secondary hypoadrenalism would, however, be reduced to 7%, if data had relied on the 
results from dynamic testing. 
The definition of gonadotropin deficiency mostly differed as concern the chosen cut-off of 
testosterone in men (Table 1c). Not unanticipated, those studies applying the lowest cut-offs 
tended to report lower prevalences of gonadotropin deficiency. Furthermore, studies 
following the general recommendation of repeated sampling in case of a low or low normal 
testosterone concentration, reported lower prevalences of gonadotropin deficiency (Klose et 
al., 2007a; van der Eerden et al., 2010), which is probably due to the low test-retest 
reproducibility (Bhasin et al., 2010; Brambilla et al., 2007) of testosterone measurements. 
Although the diagnosis of secondary hypothyroidism is challenging, the studies used very 
similar definitions, with cut-offs mostly differing according to the local reference ranges 
applied (Table 1d). Only one study differed significantly, reporting a prevalence of 22%, 
explained by a much wider definition (Lieberman et al., 2001). Applying the general definition 
(low fT4 and low/normal TSH) to this study, the prevalence would have been lowered to 12%.  
Certain antiepileptic drugs may have various side effects on the endocrine function. Given 
the relatively high incidence of posttraumatic epilepsy in TBI survivors, biochemical 
alterations induced by epilepsy in itself or the antiepileptic drugs may have confounded the 
estimated prevalence in the present TBI studies. There are, however, insufficient data to 
enable a proper evaluation of the impact of such confounder. 
Thus, diagnostic uncertainties are likely to have affected the published prevalences, and 
although plentiful in general, it is of special interest in post-TBI hypopituitarism, given that 
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the large majority of these patients were reported with isolated GHD or with only one 
additional deficit. This is in contrast to patients with objective evidence of hypothalamic-
pituitary damage, and thus a high pre-test probability of hypopituitarism, where isolated 
GHD is less frequent. 
6. Outcome studies on hypopituitarism in TBI  
Concerns have been raised whether undiagnosed and thus untreated hypopituitarism may 
contribute to the mortality and severe morbidity seen in TBI. The magnitude of such 
contribution has still not been defined, and again data are conflicting.  
Increased disability, decreased QoL and a greater likelihood of depression has been 
described in patients with posttraumatic GH deficiency (Bavisetty et al., 2008; Kelly et al., 
2006), although others have suggested that neuropsychological and QoL deficits are more 
closely associated to presence of haemorrhagic lesions on CT, than to hypopituitarism per se 
(Wachter et al., 2009). Although not taking presence of cerebral lesions into account, we 
described that when adjusted for confounders such as trauma severity, posttraumatic 
hypopituitarism remained an independent predictor of the classical phoenotypic features of 
hypopituitarism, including an unfavourable lipid and body-composition profile, as well as 
worsened QoL (Klose et al., 2007d), which could point to an association. Bondanelli et al. 
(Bondanelli et al., 2007) found that peak GH was an independent predictor of poorer 
outcome as measured by rehabilitation scales evaluating cognition, disability and functional 
dependency. Such association between cognitive function impairment and GH axis integrity 
was recently questioned by Pavlovic et al. (Pavlovic et al., 2010) who applied a very 
extensive neuropsychological battery, selected for high sensitivity for subtle brain 
dysfunction. No differences were found comparing patients with GH deficiency and those 
with normal GH function, and no correlation was found between neuropsychological 
variables and stimulated peak GH or insulinlike growth factor-I (IGF-I) levels.  
A recent study focused on another outcome measure, and found reduced aerobic- and 
endurance capacity in patients with posttraumatic isolated GHD as compared to those with 
normal pituitary function (Mossberg et al., 2008). 
Discrepancies in the reported outcome data, are likely to be explained by lack of power, 
variable diagnostic validity questioning the grouping of patients, and problems to correct 
for the enormous heterogeneity of co-morbidities in TBI patients. Furthermore, use of 
different patient reported outcome questionnaires complicates direct comparison. 
7. Treatment of pituitary insufficiency 
7.1 Acute phase 
Although pituitary hormone alterations are a very common phenomenon in the acute phase 
after TBI, the diagnosis entails plenty of problems, and currently there are no reliable 
diagnostic cut-offs for anterior pituitary hormone deficiency in critically ill patients. 
Furthermore, there is no evidence to support a clinical benefit from hormonal replacement 
therapy with GH, thyroid hormone, nor reproductive hormones in the critically ill. 
Treatment with pharmacological doses of GH has been shown to increase morbidity and 
mortality (Takala et al., 1999),  whether or not administration of thyroid hormone is 
beneficial or harmful remains controversial (De Groot, 2006; Stathatos et al., 2001), and no 
conclusive clinical benefit has been demonstrated for androgen treatment in prolonged 
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critical illness (Angele et al., 1998).  The diagnosis of adrenal failure and management of this 
disorder also remains controversial, with poor agreement among the experts. The threshold 
that best describes the patients at need for acute or chronic glucocorticoid replacement is 
still to be defined and is likely to depend on the underlying illness. The evidence of a clinical 
benefit from glucocorticoid replacement therapy in the acute phase of TBI relies on case 
reports (Agha et al., 2005b; Webster & Bell, 1997). At present time, recommendations are 
pragmatic and mainly rely on the clinical evaluation of the patient, where a combination of 
hyponatraemia, hypoglycaemia, and hypotension is highly suggestive (Agha et al., 2005b; 
Cooper & Stewart, 2003), but not prerequisite, of secondary hypoadrenalism, and should 
elicit an immediate therapeutic trial of glucocorticoid replacement. The subsequent 
treatment response should guide the decision of further treatment and follow-up. 
7.2 Chronic phase 
The negative effects of chronic glucocorticoid-, thyroid- and gonadal hormone deficiencies 
are well recognised, as is the beneficial effect from appropriate replacement therapy. Yet 
randomised clinical trials have never been performed in such classical endocrine 
deficiencies, and neither are randomised studies available to document such effect in TBI 
patients. These deficiencies and their treatment, however, have more distinct clinical 
features, than e.g. GH deficiency, which is the most frequently reported deficiency in TBI 
patients. It is associated with impaired linear growth and attainment of normal body 
composition in children, but in adults the features are less specific with reduced lean body 
mass, decreased exercise capacity, reduced bone mineral density, unfavourable changes in 
the lipid profile and decreased QoL.  
There are limited data on treatment effect in this specific subpopulation of patients with 
anterior pituitary hormone deficiency. Two studies have compared clinical and other 
outcome variables measured at baseline and after one year of hGH replacement in TBI 
patients and in patients with non-functioning pituitary adenoma (NFPA) from Pfizer 
International Metabolic (KIMS) database(Casanueva et al., 2005; Kreitschmann-Andermahr 
et al., 2008). At one-year follow-up, IGF-I SDS levels had increased to the normal range, and 
improved QoL was observed, in TBI as in NFPA patients, suggesting that TBI patients with 
GH deficiency benefit from hGH replacement in terms of improved QoL in a similar fashion 
as do NFPA patients. Worth mentioning, however, is the fact that this registry study was 
biased in having included only patients diagnosed with GHD, and this cohort is therefore 
not representative for a general cohort of TBI patients. Recently, data was published from a 
study including 23 patients with posttraumatic GH deficiency/insufficiency randomised to 
either a year of placebo or GH replacement therapy (High, Jr. et al., 2010). Data suggested 
that some of the cognitive impairments observed in these patients might be partially 
reversible with appropriate replacement therapy. Similar observations were recorded by 
Maric et al. (Maric et al., 2010). Reimunde et al. (Reimunde et al., 2011) compared the effect 
of daily neurocognitive rehabilitation plus GH replacement, with neurocognitive 
rehabilitation alone and reported larger scale improvements in the GH deficient TBI patients 
on combined treatment schedule. Although encouraging, there is still inadequate evidence 
to demonstrate that pituitary replacement therapy improves the metabolic profile, neuro-
cognitive symptoms, psychosocial problems, and work-related activities in TBI patients, and 
larger randomised placebo-controlled studies are much awaited, and crucial for proper 
evidence based clinical decisions. 
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8. When should testing and treatment be considered in patients with TBI? 
Currently no evidence exists to suggest introduction of anterior pituitary hormone screening 
in the acute phase, due to both the aforementioned diagnostic difficulties and lack of 
evidence of the beneficial effects from hormonal substitution. Adrenal insufficiency should 
be treated upon clinical suspicion. 
The temporal relationship between TBI and hypopituitarism is poorly understood. 
Longitudinal studies examining TBI patients at variable time points from the acute phase to 
years after the trauma, have reported transient, permanent, and de novo deficiencies all 
through the time span (Agha et al., 2005a; Kleindienst et al., 2009; Klose et al., 2007b; 
Tanriverdi et al., 2006). Part of this variation may be ascribed to diagnostic difficulties, 
including those caused by the stress of severe illness, but may also in some cases be related 
to medication effects, and lack of test re-test reproducibility. It is therefore often 
recommended that neuroendocrine evaluation should be performed no earlier than one year 
post trauma unless the clinical picture indicates otherwise (Ghigo et al., 2005; Ho, 2007; 
Tanriverdi et al., 2011).  
Another important issue is which patients that should be considered for neuroendocrine 
evaluation. This is particularly important considering the high incidence of TBI (> 100 in 
100,000 inhabitants). On the one hand it is of clinical importance to identify all patients that 
would benefit from relevant substitution therapy, but on the other hand it is of major socio-
oeconomic interest to ensure a cost-effective strategy. To perform pituitary testing in all TBI 
patients would be an impossible task both logistically and financially. Unfortunately, the 
area lacks valid clinical, biochemical or other predictors and it has not yet been clarified, 
which part of the TBI population that should be tested (Klose & Feldt-Rasmussen, 2008). 
Symptoms of hypopituitarism are usually very unspecific and highly overlap those of TBI 
patients in general, and can thus rarely be used for patient selection. Different markers of 
increased trauma severity, and injury location have been proposed as predictive (Bavisetty 
et al., 2008; Kelly et al., 2000; Klose et al., 2007a; Schneider et al., 2007b; Schneider et al., 
2008), but unfortunately data are very inconsistent.  
Finally, data are still awaited to document the effect of hormone replacement therapy in this 
patient category, and until such data are available, one should be cautious to introduce 
uncritical routine anterior pituitary testing and replacement therapy. Certain categories of 
patients with TBI may be at a greater risk, including those with increased ICP (Klose et al., 
2007a), CT abnormalities (Bavisetty et al., 2008), diffuse axonal injury, and those with basal 
skull fractures (Schneider et al., 2008), and should probably be regarded with a higher 
priority for pituitary assessment. 
9. Conclusion 
Anterior pituitary hormone alterations are frequently encountered in the acute phase after 
TBI. The relevance and therapeutic implications of such endocrine changes are still debated. 
Acute phase assessment of the growth hormone, thyroid, and gonadal axis is not 
recommended, as there is no evidence of a clinical benefit from replacement therapy at this 
stage. Untreated adrenal insufficiency can be life threatening. As biochemical assessment is 
difficult in the acute phase, the diagnosis should mainly be based on the clinical picture, and 
immediate treatment instituted on suspicion. 
Chronic anterior pituitary hormone deficits are reported with a much higher frequency than 
previously thought, and this has caused expert panels to propose recommendations for 
www.intechopen.com
 
The Case of Hypopituitarism in Traumatic Brain Injury 65 
hormone assessment of pituitary insufficiency and consequent appropriate replacement 
after TBI. Which subgroups of patients that should be considered for assessment, and at 
what time-point is, however, still debated.  
Introduction of a routine screening program at this stage would be tempting, but remains 
problematic. The annual incidence rate of TBI leading to hospitalisation is roughly 100 in 
100,000 inhabitants (Engberg & Teasdale, 2001), and it is thus of major socio-oeconomic 
interest to ensure a cost-effective screening strategy, as pituitary testing in all TBI patients 
would be an impossible task both logistically and economically. Much larger cohorts are 
needed for further evaluation and confirmation of reliable screening markers. Future studies 
should be designed to ensure a high diagnostic robustness for proper identification of 
reliable predictors, and to ensure that data can be generalised to an every-day TBI 
population, as the results may be highly dependent on selection criteria, confirmation of 
abnormal test results or not, and use of different diagnostic tests and criteria. Coexisting 
morbidities such as obesity and epilepsy, may also confound the results of neuroendocrine 
testing, and thus render the diagnostic process as well as the decision-making regarding 
replacement therapy difficult. Had the patients with high BMI had additional hormone 
deficiencies to GHD, and all patients diagnosed with isolated GHD been lean many of the 
reported results would have been more convincing. Finally, properly designed randomised 
intervention studies are awaited to document an effect of hormone replacement therapy in 
this patient category, and until such data are available, one should be cautious to introduce 
uncritical routine anterior pituitary testing and replacement therapy in TBI patients. 
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